Michael Yang, ViaCyte CEO
CRISPR, ViaCyte beat Vertex to the clinic with diabetes cell therapy that evades the immune system
The race to develop a cell therapy for type 1 diabetes is heating up, and the team at ViaCyte and CRISPR Therapeutics appears to have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
